Literature DB >> 11193874

Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.

M L Lara-Marquez1, M S O'Dorisio, B Karacay.   

Abstract

Vasoactive intestinal peptide (VIP) binding sites have been identified in the human thymus, but the receptor subtype and how these receptors are distributed in the human thymus subsets is unknown. To assess gene expression, distribution, and receptor regulation of the two G-protein-associated VIP receptors, VPAC1 and VPAC2 mRNAs were quantified using a novel fluorometric-based kinetic (real-time) RT-PCR. Bulk and fractionated thymocytes were stimulated via the TCR/CD3 receptor complex and anti-CD28. Our results demonstrate that thymocytes express higher levels of VPAC2 compared to VPAC1 expression in bulk thymocytes, CD4+CD8+ selected double positives (DP), and CD8 depleted thymocytes. Double negative cells express low levels of VPAC2 mRNA. We demonstrate T-cell activation-dependent down-regulation of VPAC1, but not VPAC2, in human thymocytes. This study reports the first direct evidence of a differential distribution and selective regulation of VPAC1 and VPAC2 gene expression in normal human thymocyte subsets.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193874     DOI: 10.1111/j.1749-6632.2000.tb06950.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  Radical reversal of vasoactive intestinal peptide (VIP) receptors during early lymphopoiesis.

Authors:  Emilie E Vomhof-DeKrey; Ashley R Sandy; Jarrett J Failing; Rebecca J Hermann; Scott A Hoselton; Jane M Schuh; Abby J Weldon; Kimberly J Payne; Glenn P Dorsam
Journal:  Peptides       Date:  2011-08-22       Impact factor: 3.750

2.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

3.  Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections.

Authors:  Emilie E Vomhof-DeKrey; Jodie S Haring; Glenn P Dorsam
Journal:  J Neuroimmunol       Date:  2011-03-10       Impact factor: 3.478

Review 4.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses.

Authors:  Yossan-Var Tan; Catalina Abad; Yuqi Wang; Robert Lopez; James Waschek
Journal:  Brain Behav Immun       Date:  2014-10-13       Impact factor: 7.217

6.  Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells.

Authors:  Emilie E Vomhof-DeKrey; Glenn Paul Dorsam
Journal:  Brain Behav Immun       Date:  2008-06-13       Impact factor: 7.217

Review 7.  Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review.

Authors:  Dongmei Wu; Dongwon Lee; Yong Kiel Sung
Journal:  Respir Res       Date:  2011-04-11

8.  Transcriptional modulation by VIP: a rational target against inflammatory disease.

Authors:  Hiba Ibrahim; Paul Barrow; Neil Foster
Journal:  Clin Epigenetics       Date:  2011-05-18       Impact factor: 6.551

9.  Modular transcriptional repertoire and MicroRNA target analyses characterize genomic dysregulation in the thymus of Down syndrome infants.

Authors:  Carlos Alberto Moreira-Filho; Silvia Yumi Bando; Fernanda Bernardi Bertonha; Filipi Nascimento Silva; Luciano da Fontoura Costa; Leandro Rodrigues Ferreira; Glaucio Furlanetto; Paulo Chacur; Maria Claudia Nogueira Zerbini; Magda Carneiro-Sampaio
Journal:  Oncotarget       Date:  2016-02-16

Review 10.  Pituitary Adenylate Cyclase-Activating Polypeptide: 30 Years in Research Spotlight and 600 Million Years in Service.

Authors:  Viktoria Denes; Peter Geck; Adrienn Mester; Robert Gabriel
Journal:  J Clin Med       Date:  2019-09-18       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.